The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab
Multiple sclerosis is the most common chronic demyelinating neurodegenerative central nervous system disease among young adults. Considering its extent in a relatively young population, multiple sclerosis determines a significant socioeconomic burden to the society due to the cost of disease modify...
Saved in:
Main Authors: | I. Jonušaitė, N. Giedraitienė, G. Kaubrys, R. Kizlaitienė |
---|---|
Format: | Article |
Language: | English |
Published: |
Vilnius University Press
2024-03-01
|
Series: | Neurologijos seminarai |
Subjects: | |
Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/34911 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis
by: Twan Sia, BA, et al.
Published: (2025-05-01) -
Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study
by: Hovav Azuly, et al.
Published: (2024-12-01) -
Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01) -
New specific migraine prevention: monoclonal antibodies against calcitonin gene-related peptide and its receptor
by: K. Ryliškienė, et al.
Published: (2019-12-01) -
Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis
by: Amy Perrin Ross, et al.
Published: (2025-01-01)